Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human CD30 / TNFRS8 Protein, Fc,Avitag™ (MALS verified), 25 µg  

Recombinant Biotinylated Human CD30 / TNFRS8 Protein, Fc,Avitag™ (MALS verified), 25 µg

Recombinant Biotinylated Human CD30 / TNFRS8 Protein, AA Phe 19 - Lys 379, expressed from human 293 cells (HEK293), Fc,Avitag™ (MALS verified)

Synonym
recombinant, human, protein, TNFRSF8, CD30, D1S166E, Ki-1

More details

CD0-H82F4-25

455,00 €

Background
Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

Source
Recombinant Biotinylated Human CD30, Fc,Avitag (CD0-H82F4) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2).
Predicted N-terminus: Phe 19

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 66.6 kDa. The protein migrates as 80-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet

Clinical and Translational Updates

(1) "Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates"
Saleh, Subtil, Hristov
Hum Pathol (2023)
(2) "Epstein-Barr virus-positive, CD30-positive, diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lympVegetative plaque on the left superior eyelid"
Wikholm, Thakker, Bakhshi et al
Skin Health Dis (2023) 3 (5), e277
(3) "Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists"
Fromm, de Silva, Schreiber
Front Immunol (2023) 14, 1236332
Showing 1-3 of 5967 papers.